Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASSPORT
2023-508584-72-00Phase 3Completed
- Sponsor
- CMC Ambroise Paré
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of infliximab in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD), sponsored by CMC Ambroise Paré. Primary endpoint: Ctrough of CT-P13 at Week 6. Started May 2024; status: completed.
02
Drugs
infliximab
03
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2023-508584-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508584-72-00.